We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Biocartis SA

Biocartis is a commercial stage molecular diagnostics company that develops diagnostics technology platforms for mult... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Rapid CE-Marked IVD Lung Cancer Test Delivers Results Within Three Hours

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: CE-marked IVD Idylla GeneFusion Panel is intended for fast treatment decisions in lung cancer (Photo courtesy of Biocartis)
Image: CE-marked IVD Idylla GeneFusion Panel is intended for fast treatment decisions in lung cancer (Photo courtesy of Biocartis)

Lung cancer remains the leading cause of cancer deaths, with non-small cell lung cancer (NSCLC) being the most common type of lung cancer. Gene fusions represent an important class of gene rearrangements and have become important in NSCLC, as they are linked to responses to certain targeted therapies. Their accurate and fast detection is critical to guide therapy choices, which is the reason why testing for gene rearrangements such as gene fusions is included in international NSCLC testing guidelines. However, comprehensive testing of actionable gene rearrangements in NSCLC is often complex and can require different technologies. In order to test all needed biomarkers, laboratories usually have to use different instruments which are often not available within their own lab. Using different instruments also requires having enough biopsy samples of sufficient good quality, which can be difficult to obtain, especially in NSCLC patients. Now, a rapid CE-marked IVD lung cancer testing solution for laboratories provides comprehensive testing results within 180 minutes, significantly faster than currently available testing methods which often take days or even weeks before results are available.

The fully automated Idylla GeneFusion Panel (CE-IVD) from Biocartis Group NV (Mechelen, Belgium) detects in one single cartridge ALK, ROS1, RET and METex14 skipping, a wide range of actionable targets relevant in NSCLC. Designed for use in clinical laboratories, the panel consolidates traditional testing workflows into one streamlined, fully-automated process. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. However, the panel only requires a limited amount of sample, thereby saving valuable tissue specimens.

The Idylla GeneFusion Panel detects ALK, ROS1 and RET fusions & MET exon 14 skipping in a single cartridge using only 1-3 FFPE tissue sections from patients with NSCLC. By offering results in a minimum amount of time, the panel shortens the time from sample to treatment initiation to one or two days. The panel demonstrated high concordance results in a clinical comparison study where ALK was compared with IHC, and ROS1, RET and METex14 skipping were compared with NGS.

“Turnaround time and time-to-treatment remains an important barrier to molecular testing. It has been demonstrated that 10% to 20% of advanced lung cancer patients do not receive the appropriate targeted therapy because biomarker results are not provided in a timely fashion,” said Herman Verrelst, Chief Executive Officer of Biocartis.

Related Links:
Biocartis Group NV 

Gold Supplier
hCG Whole Blood Pregnancy Test
Helminth Multiplex PCR Assay
Allplex GI-Helminth(I) Assay
Cardiac Test
ImmunTech Cardiac Triple Test

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.